Drug
Tak 667
Tak 667: highest development phase Phase 3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-667 NCT04654351 | Phase 3 | Hereditary Angioedema |
Latest
No recent events.
Follow Tak 667 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.